Product: Human growth hormone-releasing factor
BRCA1 [p Ser1387] Antibody Summary
| Immunogen |
Immunogen for this antibody was a phosphorylated synthetic peptide, which represented a portion of human Breast Cancer Gene 1 (GeneID 672) around serine 1387 according to the numbering given in entry NP_009225.1.
|
| Modification |
p Ser1387
|
| Localization |
Nuclear
|
| Predicted Species |
Equine (100%), Primate (100%). Backed by our 100% Guarantee.
|
| Clonality |
Polyclonal
|
| Host |
Rabbit
|
| Gene |
BRCA1
|
| Purity |
Immunogen affinity purified
|
| Innovators Reward |
Test in a species/application not listed above to receive a full credit towards a future purchase.
Learn about the Innovators Reward
|
Applications/Dilutions
| Dilutions |
|
| Application Notes |
Useful for Western Blot. The blocking peptide is available, catalog number NB100-225PEP.
|
Reactivity Notes
Based on 100% sequence identity, this antibody is predicted to react with Panda, Orangutan, Gorilla, Chimpanzee, Bornean orangutan and Northern white-cheeked gibbon.
Packaging, Storage & Formulations
| Storage |
Store at 4C. Do not freeze.
|
| Buffer |
Tris-Citrate/Phosphate (pH 7.0 – 8.0)
|
| Preservative |
0.09% Sodium Azide
|
| Concentration |
1.0 mg/ml
|
| Purity |
Immunogen affinity purified
|
Alternate Names for BRCA1 [p Ser1387] Antibody
- BRCA1
- BRCAI
- breast and ovarian cancer susceptibility protein 1
- breast and ovarian cancer sususceptibility protein
- breast cancer 1, early onset
- breast cancer type 1 susceptibility protein
- EC 6.3.2
- EC 6.3.2.-
- IRIS
- PNCA4
- PSCP
- subunit 1
Background
BRCA 1 contains at least two nuclear localization signals and is proposed to be a tumor suppressor protein. It is a serine phosphoprotein that undergoes hyperphosphorylation during late G1 and S phases of the cell cycle and is transiently dephosphorylated early after M phase. BRCA 1 protein alters in a qualitative and quantitative manner during cell cycle progression. The amount of BRCA protein is highest during S phase and remains elevated toward G2 / M, before it declines in early G1 phase. Inherited loss of BRCA 1 function confers an increased susceptibility for both breast and ovarian cancer.